Patents by Inventor David A. Bumcrot

David A. Bumcrot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR/CAS-related methods and compositions for treating herpes simplex virus
    Patent number: 11834649
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: December 5, 2023
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20230295725
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 21, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • PHENOTHIAZINE DERIVATIVES AND USES THEREOF
    Publication number: 20230257410
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Application
    Filed: November 16, 2022
    Publication date: August 17, 2023
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20230038993
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: February 2, 2021
    Publication date: February 9, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE
    Publication number: 20230026726
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Sickle Cell Disease (SCD) are disclosed.
    Type: Application
    Filed: February 7, 2022
    Publication date: January 26, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. FRIEDLAND, Morgan L. MAEDER, G. Grant WELSTEAD, David A. BUMCROT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10)
    Publication number: 20230025279
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Application
    Filed: March 7, 2022
    Publication date: January 26, 2023
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, David A. BUMCROT, Shen SHEN
  • CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS
    Publication number: 20230002760
    Abstract: CRISPR/Cas-related compositions and methods which provide for efficient gene editing of eukaryotic cells using modified gRNAs.
    Type: Application
    Filed: January 10, 2022
    Publication date: January 5, 2023
    Inventors: Gordon Grant Welstead, Jennifer Leah Gori, Jack Michael Heath, David A. Bumcrot
  • Phenothiazine derivatives and uses thereof
    Patent number: 11542290
    Abstract: The present invention provides phenothiazine compounds, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment of various diseases or conditions, for example ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA).
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 3, 2023
    Assignee: CAMP4 THERAPEUTICS CORPORATION
    Inventors: David A. Bumcrot, Alfica Sehgal, Donald L. Hertzog
  • Therapeutic compositions
    Patent number: 11530408
    Abstract: This application relates to therapeutic siRNA agents and methods of making and using the agents.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: December 20, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, David Bumcrot
  • GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression
    Publication number: 20220348915
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.
    Type: Application
    Filed: February 9, 2021
    Publication date: November 3, 2022
    Inventors: Jared Gollob, Gregory Hinkle, Ivanka Toudjarska, David Bumcrot
  • ASSAYS AND METHODS FOR DETERMINING ACTIVITY OF A THERAPEUTIC AGENT IN A SUBJECT
    Publication number: 20220307083
    Abstract: The invention relates to methods and assays for determining the activity of a composition comprising a therapeutic gene administered to a subject.
    Type: Application
    Filed: February 14, 2022
    Publication date: September 29, 2022
    Inventors: Dinah Sah, David Bumcrot, Alfica Sehgal
  • COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE
    Publication number: 20220273818
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 1, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee MAEDER, Rina J. MEPANI, David A. BUMCROT, Shen SHEN, Michael STEFANIDAKIS
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TMPRSS6 GENE
    Publication number: 20220251570
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 11, 2022
    Inventors: David Bumcrot, Brian Bettencourt, Ivanka Toudjarska
  • CRISPR/cas-related methods and compositions for treating herpes simplex virus
    Patent number: 11390861
    Abstract: Genome editing systems and genetic constructs that target a herpes simplex virus (HSV) viral gene, where the systems comprise one Cas9 molecule, and a gRNA molecule, compositions and cells comprising such genome editing systems and genetic constructs as well as methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering, and for preventing, treating or reducing HSV infection.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: July 19, 2022
    Assignees: EDITAS MEDICINE, INC., DUKE UNIVERSITY
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen
  • METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS
    Publication number: 20220168316
    Abstract: Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.
    Type: Application
    Filed: January 27, 2022
    Publication date: June 2, 2022
    Inventors: Alfica Sehgal, Alla A. Sigova, Igor Zlobine, Brian E. Schwartz, David A. Bumcrot, Vaishnavi Rajagopal, Yun Joon Jung, Yuichi Nishi
  • Compositions and methods for treating CEP290-associated disease
    Patent number: 11339437
    Abstract: Compositions and methods for treatment of CEP290 related diseases are disclosed.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: May 24, 2022
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, Rina J. Mepani, David A. Bumcrot, Shen Shen, Michael Stefanidakis
  • SERPINA1 SIRNAS: COMPOSITIONS OF MATTER AND METHODS OF TREATMENT
    Publication number: 20220155716
    Abstract: The technology described herein relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the Serpina1 gene, and methods of using such dsRNA compositions to inhibit expression of Serpina1.
    Type: Application
    Filed: October 5, 2021
    Publication date: May 19, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Alfica SEHGAL, David BUMCROT, Brian BETTENCOURT
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA
    Publication number: 20220135970
    Abstract: CRISPR/Cas-related compositions and methods for treatment of Usher Syndrome and/or Retinitis Pigmentosa are disclosed herein.
    Type: Application
    Filed: June 7, 2021
    Publication date: May 5, 2022
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Morgan L. MAEDER, David A. BUMCROT
  • CRISPR-CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
    Publication number: 20220106600
    Abstract: CRISPR/CAS-related compositions and methods for treatment of cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: April 7, 2022
    Inventors: G. Grant Welstead, Ari E. Friedland, Morgan L. Maeder, David A. Bumcrot
  • METHODS OF TREATING LIVER DISEASES
    Publication number: 20220107328
    Abstract: Provided herein are methods and compositions for the treating a patient with one or more conditions associated with PNPLA3, such as nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and/or alcoholic liver disease (ALD). Methods and compositions are also provided for modulating the expression of the PNPLA3 gene in a cell by altering gene signaling networks. Companion diagnostic methods, compositions and kits are also provided.
    Type: Application
    Filed: August 14, 2019
    Publication date: April 7, 2022
    Inventors: David A. Bumcrot, Alfica Sehgal, Alla A. Sigova, Brian Elliott Schwartz, Gavin Whissell, Iris Grossman, Vaishnavi Rajagopal, Cynthia Marie Smith, Mario Esteban Contreras Gamboa